Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal… Read more
Inhibitor Therapeutics Inc (INTI) - Total Assets
Latest total assets as of September 2025: $3.14 Million USD
Based on the latest financial reports, Inhibitor Therapeutics Inc (INTI) holds total assets worth $3.14 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Inhibitor Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Inhibitor Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Inhibitor Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Inhibitor Therapeutics Inc's total assets of $3.14 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Inhibitor Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhibitor Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 71.8% in 2015.
- Cash Position: Cash and equivalents constituted 98.5% of total assets in 2024, up from 67.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Inhibitor Therapeutics Inc Competitors by Total Assets
Key competitors of Inhibitor Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Inhibitor Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Inhibitor Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Inhibitor Therapeutics Inc is currently not profitable relative to its asset base.
Inhibitor Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 35.00 | 144.78 | 0.25 |
| Quick Ratio | 35.00 | 144.78 | 0.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.98 Million | $ 6.41 Million | $ -318.06K |
Inhibitor Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Inhibitor Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3348.52 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -36.4% |
| Total Assets | $5.69 Million |
| Market Capitalization | $3.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Inhibitor Therapeutics Inc's assets below their book value (0.69 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Inhibitor Therapeutics Inc's assets decreased by 36.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Inhibitor Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Inhibitor Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.69 Million | -36.37% |
| 2023-12-31 | $8.95 Million | -25.27% |
| 2022-12-31 | $11.98 Million | +20271.40% |
| 2021-12-31 | $58.78K | -55.39% |
| 2020-12-31 | $131.76K | -85.36% |
| 2019-12-31 | $899.97K | -27.01% |
| 2018-12-31 | $1.23 Million | +60.54% |
| 2017-12-31 | $768.05K | -89.53% |
| 2016-12-31 | $7.34 Million | +728.36% |
| 2015-12-31 | $885.86K | -- |